Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer
暂无分享,去创建一个
Paul J van Diest | P. V. van Diest | P. Kenemans | R. Verheijen | H. Fabry | Peter Kenemans | H. Winters | B. Hermsen | Silvia von Mensdorff-Pouilly | René H M Verheijen | Brenda B J Hermsen | Hans F J Fabry | Hay A H Winters | S. von Mensdorff‐Pouilly
[1] M. J. van de Vijver,et al. Ductal carcinoma in situ: a proposal for a new classification. , 1994, Seminars in diagnostic pathology.
[2] P. V. van Diest,et al. Multiple fibroadenomas harbouring carcinoma in situ in a woman with a family history of breast/ovarian cancer , 2002, Journal of clinical pathology.
[3] D J Schaid,et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.
[4] A. Oberg,et al. "Diabetic mastopathy," or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes. , 2002, Diabetes care.
[5] H. Ditzel,et al. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[6] M. Stratton,et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.
[7] Julian Peto,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.
[8] Susan L Neuhausen,et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Hartge,et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.
[10] D. Easton,et al. Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.
[11] W. Dupont,et al. Atypical hyperplastic lesions of the female breast: A long-term follow-up study , 1986 .
[12] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[13] L. Happerfield,et al. Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast. , 1996, British Journal of Cancer.
[14] L. Kiemeney,et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Camuto,et al. Diabetic mastopathy: a report of 5 cases and a review of the literature. , 2000, Archives of surgery.
[16] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.